TradingKey

關於 Pacira Biosciences Inc 公司

Pacira BioSciences, Inc. 是 Pacira Pharmaceuticals, Inc. 的控股公司。該公司的非阿片類治療藥物包括 EXPAREL（布比卡因脂質體注射混懸液），這是一種用於術後疼痛管理的長效局部鎮痛藥；ZILRETTA（曲安奈德緩釋注射混懸液），這是一種緩釋關節內 (IA) 皮質類固醇注射劑，用於治療 OA 膝關節疼痛；以及 Iovera，這是一種新型手持設備，可通過精確控制的低溫劑量向目標神經提供即時、長效、無藥物的疼痛控制。EXPAREL 用於多種骨科手術，包括關節重建、肩部、脊柱、四肢手術和髖部骨折。該公司正在開發干預措施來治療涉及交感神經系統的衰弱性疾病，例如心臟電風暴、慢性疼痛。其臨牀開發項目包括 PCRX-201 和基於 pMVL 的臨牀項目。

公司簡介

公司代碼PCRX

公司名稱Pacira Biosciences Inc

上市日期Feb 03, 2011

CEOMr. Frank D. Lee

員工數量790

證券類型Ordinary Share

年結日Feb 03

公司地址2000 Sierra Point Parkway

城市BRISBANE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編94005

電話16502428052

網址https://www.pacira.com/

公司代碼PCRX

上市日期Feb 03, 2011

CEOMr. Frank D. Lee

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Mark A. Kronenfeld, M.D.

Independent Director

34.90K

+40.15%

Dr. Jonathan Slonin, M.D.

Chief Medical Officer

34.69K

-12.78%

Mr. Daryl Gaugler

Executive Vice President - Commercial Operations

32.29K

-51.29%

Ms. Laura A. Brege

Independent Chairman of the Board

23.71K

+35.11%

Mr. Abraham N. (Abe) Ceesay

Independent Director

11.39K

+117.84%

Ms. Lauren Riker

Senior Vice President - Finance, Principal Accounting Officer

5.98K

-59.94%

Mr. Michael J. Yang

Independent Director

--

Mr. Shawn M. Cross

Chief Financial Officer

--

Dr. Marcelo Bigal, M.D., Ph.D.

Independent Director

--

Ms. Susan Mesco

Investor Relations

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Mark A. Kronenfeld, M.D.

Independent Director

34.90K

+40.15%

Dr. Jonathan Slonin, M.D.

Chief Medical Officer

34.69K

-12.78%

Mr. Daryl Gaugler

Executive Vice President - Commercial Operations

32.29K

-51.29%

Ms. Laura A. Brege

Independent Chairman of the Board

23.71K

+35.11%

Mr. Abraham N. (Abe) Ceesay

Independent Director

11.39K

+117.84%

Ms. Lauren Riker

Senior Vice President - Finance, Principal Accounting Officer

5.98K

-59.94%

收入明細

FY2025Q1

FY2024

FY2023

FY2022

FY2021

FY2020

業務USD

名稱

營收

佔比

EXPAREL

136.53M

0.00%

ZILRETTA

23.34M

0.00%

iovera

5.12M

0.00%

Bupivacaine liposome injectable suspension

2.60M

0.00%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

EXPAREL

136.53M

0.00%

ZILRETTA

23.34M

0.00%

iovera

5.12M

0.00%

Bupivacaine liposome injectable suspension

2.60M

0.00%

股東統計

更新時間: 7月13日週日

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

14.61%

The Vanguard Group, Inc.

11.21%

D. E. Shaw & Co., L.P.

4.89%

Renaissance Technologies LLC

4.84%

Dimensional Fund Advisors, L.P.

4.43%

Other

60.03%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

14.61%

The Vanguard Group, Inc.

11.21%

D. E. Shaw & Co., L.P.

4.89%

Renaissance Technologies LLC

4.84%

Dimensional Fund Advisors, L.P.

4.43%

Other

60.03%

股東類型

持股股東

佔比

Investment Advisor

49.40%

Hedge Fund

27.65%

Investment Advisor/Hedge Fund

25.71%

Research Firm

5.57%

Pension Fund

1.69%

Individual Investor

1.48%

Bank and Trust

1.05%

Sovereign Wealth Fund

0.32%

Holding Company

0.31%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

611

52.44M

113.25%

-16.62M

2025Q1

638

53.73M

116.03%

-16.46M

2024Q4

638

52.13M

112.66%

-21.91M

2024Q3

638

53.62M

116.22%

-11.06M

2024Q2

624

54.29M

116.65%

-6.10M

2024Q1

627

51.47M

110.71%

-7.99M

2023Q4

621

50.55M

108.88%

-6.71M

2023Q3

612

49.73M

107.18%

-6.05M

2023Q2

605

49.27M

107.14%

-5.45M

2023Q1

601

48.56M

105.72%

-5.54M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

6.77M

14.61%

-179.41K

-2.58%

Mar 31, 2025

The Vanguard Group, Inc.

5.19M

11.21%

-25.27K

-0.48%

Mar 31, 2025

D. E. Shaw & Co., L.P.

2.26M

4.89%

+6.43K

+0.29%

Mar 31, 2025

Renaissance Technologies LLC

2.24M

4.84%

+248.00K

+12.45%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.05M

4.43%

+217.22K

+11.86%

Mar 31, 2025

State Street Global Advisors (US)

1.98M

4.27%

+13.89K

+0.71%

Mar 31, 2025

DOMA Perpetual Capital Management, LLC

1.80M

3.9%

+56.22K

+3.22%

Mar 31, 2025

Balyasny Asset Management LP

1.57M

3.38%

+1.13M

+260.53%

Mar 31, 2025

Citadel Advisors LLC

1.33M

2.87%

+1.28M

+2700.84%

Mar 31, 2025

Alyeska Investment Group, L.P.

1.31M

2.83%

+1.31M

--

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

Pacer US Small Cap Cash Cows Growth Leaders ETF

2.97%

SPDR S&P Pharmaceuticals ETF

2.6%

Invesco Pharmaceuticals ETF

2.5%

Simplify Health Care ETF

2.21%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.85%

Invesco S&P SmallCap Health Care ETF

0.79%

VictoryShares Small Cap Free Cash Flow ETF

0.76%

iShares U.S. Pharmaceuticals ETF

0.56%

Royce Quant Small-Cap Quality Value ETF

0.53%

Distillate Small/Mid Cash Flow ETF

0.45%

Pacer US Small Cap Cash Cows Growth Leaders ETF

佔比2.97%

SPDR S&P Pharmaceuticals ETF

佔比2.6%

Invesco Pharmaceuticals ETF

佔比2.5%

Simplify Health Care ETF

佔比2.21%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.85%

Invesco S&P SmallCap Health Care ETF

佔比0.79%

VictoryShares Small Cap Free Cash Flow ETF

佔比0.76%

iShares U.S. Pharmaceuticals ETF

佔比0.56%

Royce Quant Small-Cap Quality Value ETF

佔比0.53%

Distillate Small/Mid Cash Flow ETF

佔比0.45%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Pacira Biosciences Inc

21.864USD

Pacira Biosciences Inc

21.864

概覽

公司

財務